|
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. |
Cediranib or placebo in combination with cisplatin and gemcitabine chemothe... |
Friday, July 17, 2015 |
The Lancet Oncology |
|
Rintoul RC, Treasure T, Macbeth F |
Multimodal treatment for malignant pleural mesothelioma |
Friday, November 6, 2015 |
The Lancet Oncology |
|
Wong HH, Halford S |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Tan CS, Gilligan D, Pacey S |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-c... |
Wednesday, September 16, 2015 |
The Lancet Oncology |
|
Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, et al. |
The expanding role of primary care in cancer control |
Sunday, October 4, 2015 |
The Lancet Oncology |
|
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et ... |
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-p... |
Wednesday, May 20, 2015 |
The Lancet Oncology |
|
Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S |
Evolving treatment options for melanoma brain metastases |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sr... |
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in p... |
Wednesday, October 28, 2020 |
The Lancet Oncology |
|
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson ... |
Gene-panel sequencing and the prediction of breast-cancer risk |
Thursday, May 28, 2015 |
The New England journal of medicine |
|
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. |
Effect of mutation order on myeloproliferative neoplasms |
Thursday, February 12, 2015 |
The New England journal of medicine |
